Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

POLYMEDCO

Polymedco is a manufacturer and distributor for clinical laboratory supplies, including diagnostic test kits and devi... read more Featured Products: More products

Download Mobile App




Fecal Immunochemical Test Detects Cancer and Polyps

By LabMedica International staff writers
Posted on 30 Aug 2017
The most commonly used noninvasive test for colorectal cancer (CRC) screening has been the guaiac fecal occult blood test (gFOBT). More...
The fecal immunochemical test (FIT) detects CRC and colorectal polyps with higher levels of sensitivity than the gFOBT, and may be more acceptable to patients.

The fecal immunochemical test (FIT), has shown to be more sensitive for CRC and colorectal polyps and may be more acceptable to patients because FIT can often be done with one sample, instead of three, and does not require dietary restrictions, such as meat avoidance. Screening can reduce incidence and mortality of CRC, but is often underused.

Scientists at the Veterans Administration San Diego Healthcare System (VASDH, San Diego, CA, USA) conducted a retrospective observational study of 7,898 patients, 50–75 years old, who were offered stool-based CRC screening as part of primary care March 2014 through January 2015. The team performed manual reviews of colonoscopy and pathology reports for veterans with positive results from the tests. The primary outcome was test completion within one year of order; secondary outcomes were positive results and detection of advanced neoplasia by diagnostic colonoscopy. The primary analysis used an intention-to-screen approach, which included all patients with test orders; as-screened analyses were also performed.

Before July 2014, when noninvasive CRC screening was offered, a three-sample Hemoccult Sensa gFOBT test was distributed at point of primary care and returned either by mail or in person. From July to August 2014, VASDHS transitioned to using a one-sample FIT (Polymedco OC auto 80, Cortland, NY, USA), also returned either by mail or in person. Colonoscopy and pathology reports were specifically reviewed to ascertain presence of any advanced neoplasia. Advanced neoplasia in this analysis included any CRC or advanced adenoma.

The investigators obtained 4,662 FIT orders and 3,236 gFOBT orders. In the intention to screen analysis, a significantly higher proportion of subjects completed a FIT (42.6%) than a gFOBT (33.4%). Advanced neoplasia was detected in a significantly higher proportion of subjects offered a FIT (0.79%) than a gFOBT (0.28%). The numbers needed to invite to achieve one additional completed test and identify one additional patient with advanced neoplasia were 11 and 196, respectively. The investigators estimate that for every 1,000 tests, FIT would yield 51 colonoscopies, compared with 42 for gFOBT.

Samir Gupta, MD, MSCS, AGAF, the study’s senior and corresponding author and a staff physician, said, “Many physicians are unaware of the difference between FIT and gFOBT, and potential advantages. One of our hopes is that the paper and other associated literature will help laboratory directors and primary care physicians to realize that making a simple switch could have big benefits for patients.” The study was published in the August 2017 issue of the journal Clinical Gastroenterology and Hepatology.


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
All-in-One Molecular System
AIO M160
Gold Member
Quantitative POC Immunoassay Analyzer
EASY READER+
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Measuring six variants from one sample may improve research efficiency and support clinical trials of amyloid biology in Alzheimer’s disease and related conditions (Image Credit: Adobe Stock)

Plasma Assay Measures Six Amyloid Beta Peptides for Alzheimer’s Treatment Research

Alzheimer’s disease research and related neurological studies often require tools that can characterize brain amyloid pathology and amyloid beta biology. Blood-based biomarker assays may help researchers... Read more

Molecular Diagnostics

view channel
Image: A new study links broad genomic sequencing before first-line therapy to longer survival, supporting its role in treatment decisions (Image Credit: Shutterstock)

Study Supports Broad Genomic Profiling Before First-Line Lung Cancer Treatment

Biomarker testing plays a critical role in advanced non-small cell lung cancer by identifying patients who may benefit from targeted therapies. However, testing only one or two genes can miss actionable... Read more

Immunology

view channel
Image: The findings underscore the importance of aligning allergy testing with clinical history and diagnostic guidelines to reduce inappropriate testing and its consequences (Image Credit: iStock)

Survey Finds Gap Between Food Allergy Testing Awareness and Clinical Practice

Food allergy evaluation can be challenging when laboratory results do not match clinical symptoms. Broad food allergy panels may detect sensitization without confirming an actual allergy, potentially leading... Read more

Industry

view channel
Image Credit: iStock

C2N Makes PrecivityAD2 Alzheimer’s Blood Test Available to Clinicians

Diagnosing Alzheimer’s disease can be challenging, particularly in patients with mild cognitive impairment or early dementia. Assessing brain amyloid pathology can guide clinical decisions, but diagnostic... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.